Fibrobiologics Inc (FBLG)

$0.25 0.00 (-0.74%)
Market Cap 17.61M
Revenue (ttm) 0.00
Net Income (ttm) -18.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 967,400
Avg Vol 1,124,780
Day's Range N/A - N/A
Shares Out 67.60M
Stochastic %K 8%
Beta -0.69
Analysts Strong Sell
Price Target $4.75

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 671 5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
Gunflint
Gunflint Mar. 18 at 9:59 AM
$FBLG They have to gain compliance to Nasdaq (1$) for 10 consecutive days by April 13th. Looks like is not gonna happen… a reverse split is likely to happen.
0 · Reply
PaulLaurent
PaulLaurent Mar. 17 at 6:48 AM
🚀📈 Top Gainers 📈🚀AH $NVGS $ISPC $DCGO $FBLG $PLBY
1 · Reply
AnUnwiseInvestor
AnUnwiseInvestor Mar. 16 at 5:54 PM
$FBLG I am the dip
0 · Reply
AnUnwiseInvestor
AnUnwiseInvestor Mar. 16 at 3:44 PM
$FBLG I bought the dip
0 · Reply
sgsam
sgsam Mar. 13 at 7:26 PM
$FBLG nothing but good news and still selling 🤦‍♂️
1 · Reply
nssy
nssy Mar. 13 at 2:34 PM
$FBLG stop selling, idiots
0 · Reply
sgsam
sgsam Mar. 12 at 11:09 PM
$FBLG bullish
0 · Reply
DARKP00L
DARKP00L Mar. 12 at 12:48 PM
$FBLG 08:47 on Mar. 12 2026 FibroBiologics Expands Its Wound Care Platform To Treat Patients With Acute, Chronic Burn Injuries #tradeideas
0 · Reply
Jdickens72
Jdickens72 Mar. 12 at 12:30 AM
$FBLG not scared one bit. Classic shakeout on a low float.
2 · Reply
tommiemac
tommiemac Mar. 10 at 7:19 PM
$FBLG open position here
0 · Reply
Latest News on FBLG
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

Mar 12, 2026, 8:30 AM EDT - 8 days ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Mar 5, 2026, 8:30 AM EST - 15 days ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Mar 2, 2026, 8:30 AM EST - 18 days ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb 26, 2026, 8:30 AM EST - 22 days ago

FibroBiologics to Present at the BIO Investment & Growth Summit

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 4:30 PM EST - 24 days ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 23, 2026, 8:30 AM EST - 25 days ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 10, 2026, 8:30 AM EST - 5 weeks ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Feb 5, 2026, 8:30 AM EST - 6 weeks ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 20, 2026, 8:30 AM EST - 2 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics CEO Issues Letter to Shareholders

Jan 7, 2026, 8:30 AM EST - 2 months ago

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 6, 2026, 8:30 AM EST - 2 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Jan 5, 2026, 8:30 AM EST - 2 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 31, 2025, 8:30 AM EST - 2 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:05 PM EST - 3 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 3 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

Dec 10, 2025, 11:36 AM EST - 3 months ago

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Dec 10, 2025, 8:30 AM EST - 3 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 4 months ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 4 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 4 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 4 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 4 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 4 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 5 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 8 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 9 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 4:35 PM EDT - 9 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

FibroBiologics to Present at the BIO International Convention 2025

Jun 16, 2025, 9:50 AM EDT - 9 months ago

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Jun 9, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 16, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:30 PM EDT - 11 months ago

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 11 months ago

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics Presents at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 11 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Apr 11, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Apr 8, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

Apr 2, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:25 PM EDT - 1 year ago

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Mar 27, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Announces 2025 Annual Meeting of Stockholders

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Mar 21, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

Mar 4, 2025, 8:30 AM EST - 1 year ago

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

Gunflint
Gunflint Mar. 18 at 9:59 AM
$FBLG They have to gain compliance to Nasdaq (1$) for 10 consecutive days by April 13th. Looks like is not gonna happen… a reverse split is likely to happen.
0 · Reply
PaulLaurent
PaulLaurent Mar. 17 at 6:48 AM
🚀📈 Top Gainers 📈🚀AH $NVGS $ISPC $DCGO $FBLG $PLBY
1 · Reply
AnUnwiseInvestor
AnUnwiseInvestor Mar. 16 at 5:54 PM
$FBLG I am the dip
0 · Reply
AnUnwiseInvestor
AnUnwiseInvestor Mar. 16 at 3:44 PM
$FBLG I bought the dip
0 · Reply
sgsam
sgsam Mar. 13 at 7:26 PM
$FBLG nothing but good news and still selling 🤦‍♂️
1 · Reply
nssy
nssy Mar. 13 at 2:34 PM
$FBLG stop selling, idiots
0 · Reply
sgsam
sgsam Mar. 12 at 11:09 PM
$FBLG bullish
0 · Reply
DARKP00L
DARKP00L Mar. 12 at 12:48 PM
$FBLG 08:47 on Mar. 12 2026 FibroBiologics Expands Its Wound Care Platform To Treat Patients With Acute, Chronic Burn Injuries #tradeideas
0 · Reply
Jdickens72
Jdickens72 Mar. 12 at 12:30 AM
$FBLG not scared one bit. Classic shakeout on a low float.
2 · Reply
tommiemac
tommiemac Mar. 10 at 7:19 PM
$FBLG open position here
0 · Reply
MasterOfstealth
MasterOfstealth Mar. 7 at 8:27 AM
$FBLG
0 · Reply
McMillion1
McMillion1 Mar. 7 at 2:09 AM
$FBLG
0 · Reply
SocioCobb
SocioCobb Mar. 7 at 12:45 AM
$FBLG
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 6 at 7:00 PM
$FBLG Q4 '25 Earnings Results & Recap FibroBiologics reported a net loss of $18.6M for the year ended December 31, 2025, an increase from $11.2M in 2024, with cash and cash equivalents at $4.9M.
0 · Reply
Wnt531
Wnt531 Mar. 6 at 2:59 PM
$FBLG Recent Form 4 filings show insiders loading shares of FibroBiologics. When the people closest to the company start buying on the open market, it usually signals confidence in what’s coming next.
3 · Reply
WeAllFallDown
WeAllFallDown Mar. 6 at 2:37 PM
$FBLG I have held for some time, insiders buying...huh...maybe...
0 · Reply
MOTP
MOTP Mar. 6 at 2:13 PM
$FBLG 10x
0 · Reply
sgsam
sgsam Mar. 6 at 9:08 AM
$PSTV $FBLG insider buying up Fblg
0 · Reply
sgsam
sgsam Mar. 6 at 8:53 AM
$FBLG bullish insiders buying up
0 · Reply
sgsam
sgsam Mar. 5 at 8:43 PM
$FBLG
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 1:44 PM
$FBLG 08:32 on Mar. 05 2026 FibroBiologics Completes Onboarding Of Clinical Sites For Phase 1/2 Clinical Trial Evaluating Safety And Efficacy Of CYWC628 For Treatment Of Refractory DFUs #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 5 at 1:31 PM
$FBLG - FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
0 · Reply